Regumate Porcine, 0.4% w/v Oral Solution

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: VMD (Veterinary Medicines Directorate)

Aktif bileşen:

Altrenogest

Mevcut itibaren:

MSD Animal Health UK Limited

ATC kodu:

QG03DX90

INN (International Adı):

Altrenogest

Farmasötik formu:

Oral suspension

Reçete türü:

POM-V - Prescription Only Medicine – Veterinarian

Terapötik grubu:

Pigs

Terapötik alanı:

Hormone sex

Yetkilendirme durumu:

Authorized

Yetkilendirme tarihi:

1985-11-12

Ürün özellikleri

Revised: March 2021
AN: 01885/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Regumate Porcine, 0.4% w/v oral solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENTS
%W/V
Altrenogest
0.4
OTHER INGREDIENTS
Butylated hydroxytoluene (E321)
0.007
Butylated hydroxyanisole (E320)
0.007
Each 5ml dose provides 20mg Altrenogest.
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral solution.
Clear, pale yellow, odourless solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the synchronisation of oestrus and improvement of litter size in
sexually mature
gilts.
For the synchronisation of oestrus and improvement of farrowing rate
and litter size
in sows.
4.3
CONTRA-INDICATIONS
Do not administer to male animals.
Do not administer to pregnant sows or those suffering from uterine
infection.
Part-consumed feed must be disposed of with other waste feed and not
given to
other animals.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
None
Revised: March 2021
AN: 01885/2020
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
(i)
Special precautions for use in animals
Not applicable.
(ii)
Special precautions to be taken by the person administering the
medicinal
product to the animals
•
Women who are pregnant, or suspected to be pregnant, should not use
the
product. Women of childbearing age should handle the product with
extreme
care. The product should not be handled by persons with known or
suspected
progesterone-dependent tumours or thrombo-embolic disorders.
•
Direct contact with the skin should be avoided. Personal protective
clothing
(gloves and overalls) must be worn when handling the product. Porous
gloves
may let this product pass through. Transcutaneous absorption may be
even
higher when the area is covered by an occlusive material, such as
latex or
rubber gloves. Accidental spillage on the skin should be washed off
immediately
with soap and water. Wash hands after treatment and before me